Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : ZT-01
Therapeutic Area : Endocrinology
Study Phase : Phase I
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Zucara Therapeutics Reports Positive Results from Phase 1b Trial of ZT-01
Details : Data from 18 subjects that completed all three hypoglycemic challenge (clamp) procedures demonstrated that nearly 90% of subjects had a meaningful increase in glucagon following ZT-01 compared to placebo.
Brand Name : ZT-01
Molecule Type : Undisclosed
Upfront Cash : Not Applicable
June 22, 2022
Lead Product(s) : ZT-01
Therapeutic Area : Endocrinology
Highest Development Status : Phase I
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : ZT-01
Therapeutic Area : Endocrinology
Study Phase : Phase I
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Zucara Therapeutics Doses First Patients in Phase 1b Trial of ZT-01
Details : Other study objectives include further evaluation of the safety and tolerability of ZT-01 and evaluation of symptoms and other hormones related to hypoglycemia. Topline results are expected in the first quarter of 2022.
Brand Name : ZT-01
Molecule Type : Undisclosed
Upfront Cash : Not Applicable
July 28, 2021
Lead Product(s) : ZT-01
Therapeutic Area : Endocrinology
Highest Development Status : Phase I
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : ZT-01
Therapeutic Area : Endocrinology
Study Phase : Phase I
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Zucara Therapeutics Successfully Completes Single and Multiple Ascending Dose Phase 1 Trial of ZT-01
Details : ZT-01, a first-in-class, once-daily therapeutic to prevent insulin-induced hypoglycemia in patients using insulin therapy. ZT-01 is designed to inhibit somatostatin, and restores glucagon secretion to prevent hypoglycemia.
Brand Name : ZT-01
Molecule Type : Undisclosed
Upfront Cash : Not Applicable
May 26, 2021
Lead Product(s) : ZT-01
Therapeutic Area : Endocrinology
Highest Development Status : Phase I
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : ZT-01
Therapeutic Area : Endocrinology
Study Phase : Undisclosed
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Zucara Therapeutics Expands ZT-01 Development Program to Type 2 Diabetes
Details : The expansion of our ZT-01 development program is based on promising results in a preclinical model of T2D and represents the potential to benefit a substantially larger population.
Brand Name : ZT-01
Molecule Type : Undisclosed
Upfront Cash : Not Applicable
November 02, 2020
Lead Product(s) : ZT-01
Therapeutic Area : Endocrinology
Highest Development Status : Undisclosed
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : ZT-01
Therapeutic Area : Endocrinology
Study Phase : Phase I
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Zucara Therapeutics Doses First Subject in Phase 1 Trial of ZT-01
Details : The study employs a single ascending dose (“SAD”) and multiple ascending dose (“MAD”) trial design and will investigate the safety, tolerability, pharmacokinetics and pharmacodynamics of ZT-01.
Brand Name : ZT-01
Molecule Type : Undisclosed
Upfront Cash : Not Applicable
September 29, 2020
Lead Product(s) : ZT-01
Therapeutic Area : Endocrinology
Highest Development Status : Phase I
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
LOOKING FOR A SUPPLIER?